首页 > 抗体蛋白 > 抗体
PE/Cyanine7 anti-mouse CD86 Antibody
产品名称:
PE/Cyanine7 anti-mouse CD86 Antibody
产品类别:
抗体
产品编号:
105013
产品应用:
105013
[价格]
规格 价格 库存
25µg ¥ 1128 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 105051-105056).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. Kuo PC, et al. 2021. Brain Commun. 3:fcab187. PubMed
  2. Zhang Z, et al. 2022. Front Pharmacol. 13:906625. PubMed
  3. Giorgetti E, et al. 2020. Cell Reports. 29(6):1539-1554.e7.. PubMed
  4. Amir M, et al. 2020. Biochem Biophys Res Commun. 527:1000. PubMed
  5. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  6. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  7. Limon JJ et al. 2019. Cell host & microbe. 25(3):377-388 . PubMed
  8. Kim CC et al. 2019. Cell Rep. 27(5):1446-1460 . PubMed
  9. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  10. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  11. Palm A, et al. 2016. Sci Rep. 10.1038/srep20531. PubMed
  12. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  13. Li K, et al. 2022. J Immunother Cancer. 10:. PubMed
  14. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  15. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  16. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  17. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  18. Zhang X, et al. 2022. Cells. 11:. PubMed
  19. Nguyen TKT, et al. 2020. Am J Pathol. 286:190. PubMed
  20. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  21. Li Z, et al. 2022. J Exp Clin Cancer Res. 41:74. PubMed
  22. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  23. Polavaram NS, et al. 2021. Bone Res. 9:24. PubMed
  24. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  25. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
  26. Trabucco S, Gerstein R, Zhang H 2016. J Immunol. 197: 1699 - 1707. PubMed
  27. Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed
  28. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  29. Guo L, et al. 2021. Vaccines (Basel). 9:. PubMed
  30. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  31. Fox C, et al. 2016. J Control Release. 244:98-107. PubMed
  32. Zhang J, et al. 2018. Sci Rep. 8:2373. PubMed
  33. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  34. Olson WJ, et al. 2019. Cell Rep. 28:2878. PubMed
  35. Lee W, et al. 2021. PLoS Pathog. 17:e1009168. PubMed
  36. Toki S, et al. 2013. Nanomedicine. 9:1235. PubMed
  37. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  38. Kelly SH, et al. 2021. ACS Biomater Sci Eng. 7:1876. PubMed
  39. Tukaramrao DB, et al. 2021. Cancers (Basel). 13:. PubMed
  40. Yang X, et al. 2022. Front Immunol. 13:856230. PubMed
  41. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  42. Ma Y, et al. 2022. Front Immunol. 13:816952. PubMed
  43. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  44. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  45. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  46. Ryu S, et al. 2021. eLife. 0.416666666666667. PubMed
  47. Qi H, et al. 2020. Cell Reports. 31(6):107621. PubMed
  48. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  49. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  50. Smith LK, et al. 2021. Elife. 10:. PubMed
  51. Lu H, et al. 2011. Toxicol Appl Pharmacol. 255:251. PubMed
  52. Zamora-Chimal J, et al. 2017. Immunobiology. 222(2):454-462. PubMed
  53. Perper SJ, et al. 2019. J Immunol. 203:58. PubMed
  54. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  55. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
RRID
AB_439782 (BioLegend Cat. No. 105013) AB_439783 (BioLegend Cat. No. 105014)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
UniProt
View information about CD86 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线